ALICIA MCDANIEL: Open Payments
NPI 1467842476 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$961 in 46 payments from 21 companies in 2025. Trend: 2023 $1,331 · 2024 $2,052 · 2025 $961
Food & beverage: $961
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $110 |
| ABBVIE INC. | 5 | $108 |
| Teva Pharmaceuticals USA, Inc. | 6 | $92 |
| ARGENX US, INC. | 4 | $88 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| Neurelis, Inc. | 3 | $59 |
| Alexion Pharmaceuticals, Inc. | 2 | $46 |
| GE HEALTHCARE | 2 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $34 |
Products named: HYQVIA, AUSTEDO XR, VYVGART HYTRULO, BOTOX, Zilbrysq, LEQVIO, VALTOCO, ULTOMIRIS.
Industry payments across MS — which companies pay providers there.
